

Routine Schedule

Age*	Vaccine	Schedule		Notes
6 months–4 years	Pfizer–Infant/Toddler	1st Dose	3-8 weeks [^] → 2nd Dose	≥8 weeks → 3rd Initial Dose Pfizer Bivalent ^β
6 months–5 years	Moderna–Infant/Toddler	1st Dose	4-8 weeks [^] → 2nd Dose	<p>Bivalent Booster[†]</p> <p>Moderna:</p> <ul style="list-style-type: none"> ● 6 months–5 years ● 6+ years <p>Pfizer:</p> <ul style="list-style-type: none"> ● 5-11 years ● 12+ years <p>(For people who previously received a monovalent booster dose(s), the bivalent booster is administered at least 2 months after the last monovalent booster dose.)</p>
5–11 years	Pfizer–Pediatric	1st Dose	3-8 weeks [^] → 2nd Dose	
6–11 years	Moderna–Pediatric	1st Dose	4-8 weeks [^] → 2nd Dose	
12+ years	Moderna–Adol/Adult	1st Dose	4-8 weeks [^] → 2nd Dose	
12+ years	Pfizer/Adol/Adult	1st Dose	3-8 weeks [^] → 2nd Dose	
12+ years	Novavax	1st Dose	3-8 weeks [^] → 2nd Dose	
18+ years	Janssen (J&J) Pfizer/Moderna/Novavax preferred ^{***}	1st Dose		

* See schedules for children in transition from a younger to older age group.

** Although use of mRNA COVID-19 and Novavax vaccines is preferred, the Janssen vaccine may be offered in [some situations](#).

† For people who have not received any booster doses and are unable or unwilling to receive bivalent booster vaccine, the [monovalent Novavax booster may be administered as a single booster dose](#) at least 6 months after completion of the primary series to people 18 years and older.

[^] An 8-week interval may be preferable for some people, especially for males 12-39 years.

^β Children who have already received 3 monovalent doses are not eligible for the Pfizer bivalent vaccine at this time.

View [Interim Clinical Considerations for Use of COVID-19 Vaccines](#) for details. Schedule is subject to change.

COVID-19 Vaccine Timing

Schedule if Moderately or Severely Immunocompromised

Age*	Vaccine	Schedule				
6 months–4 years	Pfizer– Infant/Toddler	1st Dose	3 weeks	2nd Dose	≥8 weeks	3rd Initial Dose ● Pfizer Bivalent ^β
6 months–5 years	Moderna– Infant/Toddler	1st Dose	4 weeks	2nd Dose	≥4 weeks	3rd Dose
5–11 years	Pfizer– Pediatric	1st Dose	3 weeks	2nd Dose	≥4 weeks	3rd Dose
6–11 years	Moderna– Pediatric	1st Dose	4 weeks	2nd Dose	≥4 weeks	3rd Dose
12+ years	Moderna– Adol/Adult	1st Dose	4 weeks	2nd Dose	≥4 weeks	3rd Dose
12+ years	Pfizer/ Adol/Adult	1st Dose	3 weeks	2nd Dose	≥4 weeks	3rd Dose
12+ years	Novavax	1st Dose	3 weeks	2nd Dose		
18+ years	Janssen (J&J) Pfizer/Moderna/ Novavax preferred**	1st Dose	4 weeks	2nd Dose of Moderna/Pfizer		

Bivalent Booster[†]

Moderna:

- 6 mos–5 yrs
- 6+ years

Pfizer:

- 5-11 years
- 12+ years

(For people who previously received a monovalent booster dose(s), the bivalent booster is administered at least 2 months after the last monovalent booster dose.)

* See schedules for children in transition from a younger to older age group.

** Although use of mRNA COVID-19 and Novavax vaccines is preferred, the Janssen vaccine may be offered in [some situations](#).

† For people who have not received any booster doses and are unable or unwilling to receive bivalent booster vaccine, the [monovalent Novavax booster may be administered as a single booster dose](#) at least 6 months after completion of the primary series to people 18 years and older.

β Children who have already received 3 monovalent doses are not eligible for the Pfizer bivalent vaccine at this time.

View [Interim Clinical Considerations for Use of COVID-19 Vaccines](#) for details. Schedule is subject to change.